Prof. ŞUAYİB YALÇIN

Publication Network

Articles 211

1. Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

İcli M. C., GÜVEN D. C., Akyildiz A., Gürbüz A. F., Majidova N., Kıdı M. M., et al.

Journal of Clinical Medicine , vol.15, no.4, 2026 (SCI-Expanded, Scopus)

2. Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

Ökten İ. N., Baydaş T., Yıldırım M. E., Bilir C., YALÇIN Ş., ÇUBUKÇU E., et al.

Journal of Clinical Medicine , vol.15, no.2, 2026 (SCI-Expanded, Scopus)

3. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Efil S. C., Kus F., Koylu B., Durukan B. M., Bayram S., Guzel H. G., et al.

Cancers , vol.18, no.1, 2026 (SCI-Expanded, Scopus)

4. Design, characterization, and in vitro/in vivo evaluation of HER2-targeted immunoliposomes co-functionalized with trastuzumab and iRGD for enhanced delivery of oxaliplatin in gastric cancer therapy

Fidan Y., Aras I. A., SİLİNDİR GÜNAY M., TİMUR S. S., ÖZTÜRK S., ESENDAĞLI G., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.113, 2025 (SCI-Expanded, Scopus) Sustainable Development

5. Incidence of Unexpected Lymph Node Positivity and Its Prognostic Impact in Patients Undergoing Pulmonary Metastasectomy

Kumbasar U., DİZDAR Ö., Uysal S., Yilmaz Y., Aydar I., KAŞIKCI ÇAVDAR M., et al.

INDIAN JOURNAL OF SURGERY , 2025 (SCI-Expanded, Scopus)

6. Adjuvant Gemcitabine-cisplatin Combination for Biliary Tract Cancer: A Real Life Experience

Kuş F., Yildirim H. c., Akyildiz A., Tatar O. D., Ozmen A., Sirvan F., et al.

Acta haematologica oncologica Turcica , vol.58, no.2, pp.121-126, 2025 (TRDizin)

7. Expert opinion on the current conceptual, clinical and therapeutic aspects of disease related malnutrition and muscle loss: a multidisciplinary perspective

Doganay M., HALİL M. G., Kaymak C., Selek U., TOPÇUOĞLU M. A., YALÇIN Ş.

FRONTIERS IN NUTRITION , vol.12, 2025 (SCI-Expanded, Scopus)

8. Bioinformatics Analysis of IGSF9B Gene in Patients Diagnosed with Colorectal Carcinoma

Yay F., Kuş F., Şahin G., Yildirim H. c., yalcin s.

Uluslararası Hematoloji-Onkoloji Dergisi , vol.35, no.2, pp.75-85, 2025 (SCI-Expanded, Scopus, TRDizin)

9. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy

AKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.

JOURNAL OF CLINICAL MEDICINE , no.9, 2025 (SCI-Expanded, Scopus)

10. Multidisciplinary Approach to Glucagonoma: A Case Report

Yazarkan Y., ERTÜRK B., Sonmez G., DİNÇER H. A., ÜNLÜTÜRK U., BOZKURT M. F., et al.

ENDOCRINOLOGY RESEARCH AND PRACTICE , vol.29, no.2, pp.149-152, 2025 (ESCI, TRDizin)

11. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , no.4, pp.129-137, 2025 (SCI-Expanded)

12. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines

KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.35, no.1, pp.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)

13. THSD7A as a novel prognostic factor for colorectal carcinoma

AKTEPE O. H., KURTULAN O., DAMA P. E., ARSLAN A. M., ATAĞ AKYÜREK E., ÜNER M., et al.

BMC GASTROENTEROLOGY , no.1, 2025 (SCI-Expanded, Scopus)

14. **A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301).**

Kim T. W., Price T., Grasselli J., Masuishi T., Kwok G. W., Yalcin S., et al.

JOURNAL OF CLINICAL ONCOLOGY , no.4_SUPPL, 2025 (SCI-Expanded, Scopus)

15. A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications

Yildirim H. C., GÜNENÇ D., Almuradova E., Sutcuoglu O., YALÇIN Ş.

MEDICINA-LITHUANIA , no.3, 2025 (SCI-Expanded, Scopus)

16. Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted therapy

Yay F., Yildirim H. c., KUŞ F., YALÇIN Ş.

BIOMARKERS , no.2, pp.147-166, 2025 (SCI-Expanded, Scopus)

17. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , no.1, pp.81-89, 2025 (SCI-Expanded)

18. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial

YILMAZ F., YAŞAR S., Mandel N. M., Kacan T., Ozdemir M., DOĞU G. G., et al.

TARGETED ONCOLOGY , vol.19, pp.957-964, 2024 (SCI-Expanded, Scopus)

19. Assessment of the Clinicopathologic Characteristics and Survival Rates of Colorectal Cancer Among Syrian Refugees and Turkish Population in Gaziantep Province

Karan C., Okten I. N., KESEN O., Celikyurek A., Teker F., YALÇIN Ş.

JCO GLOBAL ONCOLOGY , vol.10, 2024 (ESCI, Scopus)

20. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.

SUPPORTIVE CARE IN CANCER , vol.32, no.7, 2024 (SCI-Expanded, Scopus) Sustainable Development

21. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., et al.

CANCERS , vol.16, no.12, 2024 (SCI-Expanded, Scopus)

22. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review

GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., et al.

ONCOLOGIST , vol.29, 2024 (SCI-Expanded, Scopus)

23. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study

ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.54, no.5, pp.562-568, 2024 (SCI-Expanded, Scopus) Sustainable Development

24. Long-term results of liver thermal ablation in patients with hepatocellular carcinoma and colorectal cancer liver metastasis regarding spatial features and tumor-specific variables

AKHAN O., ERDEMİR A. G., KARAHAN S., ÜNAL E., ÇİFTÇİ T. T., AKINCI D., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , vol.30, no.3, pp.183-192, 2024 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

25. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy

Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., et al.

International Journal of Clinical Oncology , 2024 (SCI-Expanded, Scopus)

26. A Post-International Gastrointestinal Cancers Conference (IGICC) Position Statements '

YALÇIN Ş., Lacin S., Kaseb A. O., PEYNİRCİOĞLU B., Cantasdemir M., ÇİL B. E., et al.

JOURNAL OF HEPATOCELLULAR CARCINOMA , vol.11, pp.953-974, 2024 (SCI-Expanded, Scopus)

27. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.

INTEGRATIVE CANCER THERAPIES , vol.23, 2024 (SCI-Expanded, Scopus)

28. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.

Vascular , 2024 (SCI-Expanded, Scopus)

29. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology

YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.

Irish Journal of Medical Science , vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded, Scopus) Sustainable Development

30. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer

André T., Pietrantonio F., Avallone A., Gumus M., Wyrwicz L., Kim J. G., et al.

Future Oncology , vol.19, no.37, pp.2445-2452, 2023 (SCI-Expanded, Scopus)

31. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.

Medicine , vol.102, no.45, 2023 (SCI-Expanded, Scopus)

32. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.

Anti-cancer drugs , vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded, Scopus)

33. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.

Current Oncology , vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded, Scopus)

34. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , vol.6, no.4, pp.170-176, 2023 (Scopus)

35. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.

The oncologist , vol.28, no.10, pp.875-884, 2023 (SCI-Expanded, Scopus)

36. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded, Scopus)

37. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , vol.34, no.6, pp.783-790, 2023 (SCI-Expanded, Scopus)

38. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , vol.102, no.18, 2023 (SCI-Expanded, Scopus)

39. Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey

Kutluk T., ŞAHİN B., Kirazli M., Ahmed F., Aydin S., Yesil Çinkir H., et al.

JAMA network open , vol.6, no.5, 2023 (SCI-Expanded, Scopus)

40. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , vol.47, no.3, 2023 (SCI-Expanded, Scopus) Sustainable Development

41. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , vol.23, no.3, pp.243-256, 2023 (SCI-Expanded, Scopus) Sustainable Development

42. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., et al.

JOURNAL OF CHEMOTHERAPY , vol.35, no.2, pp.142-149, 2023 (SCI-Expanded, Scopus)

43. Long-term results of radiofrequency and microwave ablation of colorectal cancer liver metastasis

ERDEMİR A. G., KARAHAN S., ÜNAL E., ÇİFTÇİ T. T., AKINCI D., YALÇIN Ş., et al.

International Journal of Gastrointestinal Intervention , vol.12, no.3, pp.130-139, 2023 (ESCI, Scopus)

44. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations

KAHRAMAN S., Bardakci M., Aykan M. B., YAŞAR S., Erol C., Hizal M., et al.

Journal of cancer research and therapeutics , vol.19, no.2, pp.347-354, 2023 (SCI-Expanded, Scopus)

45. Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence-Based Protocol (PRONTO)

Muscaritoli M., Bar-Sela G., Battisti N. M. L., Belev B., Contreras-Martínez J., Cortesi E., et al.

Cancers , vol.15, no.2, 2023 (SCI-Expanded, Scopus)

46. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.

Journal of Oncological Science , vol.9, no.2, pp.72-78, 2023 (Scopus, TRDizin)

47. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , vol.9, no.1, pp.33-37, 2023 (Scopus, TRDizin)

48. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.

Frontiers in Molecular Biosciences , vol.9, 2022 (SCI-Expanded, Scopus)

49. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , vol.15, no.4, pp.307-310, 2022 (ESCI, Scopus)

50. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , vol.66, pp.85-88, 2022 (SCI-Expanded, Scopus)

51. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine

Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., et al.

TRANSLATIONAL ONCOLOGY , vol.25, 2022 (SCI-Expanded, Scopus)

52. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.17, 2022 (SCI-Expanded, Scopus)

53. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

ÖZET A., DANE F., Aykan N. F., YALÇIN Ş., EVRENSEL T., ÖZKAN M., et al.

FUTURE ONCOLOGY , vol.18, no.29, pp.3267-3276, 2022 (SCI-Expanded, Scopus)

54. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., et al.

JOURNAL OF PERSONALIZED MEDICINE , vol.12, no.8, 2022 (SCI-Expanded, Scopus)

55. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.15, 2022 (SCI-Expanded, Scopus)

56. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.4, pp.785-793, 2022 (SCI-Expanded, Scopus) Sustainable Development

57. Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care

Prado C. M., Laviano A., Gillis C., Sung A. D., Gardner M., YALÇIN Ş., et al.

SUPPORTIVE CARE IN CANCER , vol.30, no.4, pp.3073-3083, 2022 (SCI-Expanded, Scopus)

58. Classification of early-stage colon cancer with Immunoscore (R): clinical evidence and case studies

YALÇIN Ş., Philip P. A., Athanasiadis I., Bazarbashi S., Shamseddine A.

FUTURE ONCOLOGY , vol.18, pp.613-623, 2022 (SCI-Expanded, Scopus) Sustainable Development

59. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study

Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4, 2022 (SCI-Expanded, Scopus)

60. Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data

Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4, 2022 (SCI-Expanded, Scopus) Sustainable Development

61. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients

Tsaousis G. N., Papadopoulou E., Agiannitopoulos K., Pepe G., Tsoulos N., Boukovinas I., et al.

CANCER GENOMICS & PROTEOMICS , vol.19, no.1, pp.60-78, 2022 (SCI-Expanded, Scopus)

62. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , vol.8, no.3, pp.143-147, 2022 (Scopus, TRDizin)

63. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.6, no.1, pp.59-63, 2022 (ESCI, TRDizin) Sustainable Development

64. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.

Turkish Journal of Medical Sciences , vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded, Scopus, TRDizin)

65. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)

66. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.

ANTI-CANCER DRUGS , vol.33, no.1, 2022 (SCI-Expanded, Scopus)

67. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.168, 2021 (SCI-Expanded, Scopus) Sustainable Development

68. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

69. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

70. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department

ÖCAL O., Eldem G., KARAGÖZ A. H., KILIÇKAP S., YALÇIN Ş., BALKANCI F., et al.

CUREUS , vol.13, no.9, 2021 (ESCI)

71. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded, Scopus) Sustainable Development

72. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded, Scopus) Sustainable Development

73. Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms

GÜVEN D. C., YALÇIN Ş.

INTERNAL MEDICINE JOURNAL , vol.51, no.8, pp.1365-1366, 2021 (SCI-Expanded, Scopus) Sustainable Development

74. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Abali H., YALÇIN Ş., Onal H. C., Dane F., Oksuzoglu B., ÖZDEMİR N., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.44, no.7, pp.301-307, 2021 (SCI-Expanded, Scopus) Sustainable Development

75. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

Kefeli U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded, Scopus) Sustainable Development

76. Artificial intelligence method to predict overall survival of hepatocellular carcinoma

ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.

Hepatology Forum , vol.2, no.2, pp.64-68, 2021 (Scopus)

77. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.36, 2021 (SCI-Expanded, Scopus)

78. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J. S., et al.

ONCOLOGIST , vol.26, no.5, 2021 (SCI-Expanded, Scopus) Sustainable Development

79. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer

Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, pp.510-515, 2021 (SCI-Expanded, Scopus) Sustainable Development

80. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer

KAHRAMAN S., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.14, pp.4149-4162, 2021 (SCI-Expanded, Scopus)

81. V600E and Non-V600E BRAF Mutations in Colorectal Cancer: Clinicopathologic Correlations in a Single Institution

ŞİMŞEK C., LAÇİN Ş., Ece E., YALÇIN Ş.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.31, no.1, pp.43-49, 2021 (SCI-Expanded, Scopus, TRDizin)

82. Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center Experience

HÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.31, no.3, pp.178-184, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

83. Machine Learning Models Predict Early Postoperative Relapse in Pancreatic Cancer

BALABAN H. Y., GÜVEN D. C., CEYLAN F., ÇAKIR İ. Y., ŞAHİN T. K., DİZDAR Ö., et al.

Journal of oncological sciences , vol.7, 2021 (Scopus, TRDizin)

84. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients

Abdel-Wahab R., Hassan M. M., George B., Pestana R. C., Xiao L., Lacin S., et al.

ONCOLOGY , vol.98, no.12, pp.836-846, 2020 (SCI-Expanded, Scopus)

85. The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer

Lacin S., YALÇIN Ş.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT , vol.19, 2020 (SCI-Expanded, Scopus) Sustainable Development

86. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience

AKIN TELLİ T., Esin E., YALÇIN Ş.

BALKAN MEDICAL JOURNAL , vol.37, no.5, pp.281-286, 2020 (SCI-Expanded, Scopus, TRDizin)

87. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Tabernero J., Alsina M., Shitara K., Doi T., Dvorkin M., Mansoor W., et al.

GASTRIC CANCER , vol.23, no.4, pp.689-698, 2020 (SCI-Expanded, Scopus)

88. Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61

ŞAHİN T. K., AKTEPE O. H., Uckun F. M., YALÇIN Ş.

ANTI-CANCER DRUGS , vol.31, no.6, pp.609-616, 2020 (SCI-Expanded, Scopus) Sustainable Development

89. Stereotactic ablative radiotherapy for bone metastasis of gastrointestinal stromal tumor: Case report and review of the literature

YILMAZ M. T., GÜLTEKİN M., YALÇIN Ş., TUNCEL M., Gedikoglu G., YILDIZ F., et al.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.25, no.3, pp.331-335, 2020 (ESCI, Scopus)

90. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Dane F., Ozgurdal K., YALÇIN Ş., BENEKLİ M., Aykan N. F., YÜCEL İ., et al.

BMJ OPEN , vol.10, no.3, 2020 (SCI-Expanded, Scopus)

91. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

YALÇIN Ş., DANE F., Oksuzoglu B., Ozdemir N. Y., Isikdogan A., ÖZKAN M., et al.

BMC CANCER , vol.20, no.1, 2020 (SCI-Expanded, Scopus)

92. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience

Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.2, pp.91-98, 2020 (SCI-Expanded, Scopus, TRDizin)

93. The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer

Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.30, no.2, pp.94-102, 2020 (SCI-Expanded, Scopus, TRDizin)

94. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study

Lacin S., YALÇIN Ş., Karakas Y., Hassan M. M., Amin H., Mohamed Y. I., et al.

JOURNAL OF HEPATOCELLULAR CARCINOMA , vol.7, pp.143-153, 2020 (SCI-Expanded)

95. Nutritional Aspect of Cancer Care in Medical Oncology Patients

YALÇIN Ş., GÜMÜŞ M., Oksuzoglu B., ÖZDEMİR F., EVRENSEL T., Sarioglu A. A., et al.

CLINICAL THERAPEUTICS , vol.41, no.11, pp.2382-2396, 2019 (SCI-Expanded, Scopus)

96. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann R. P., Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., et al.

CLINICAL COLORECTAL CANCER , vol.18, no.3, pp.183-194, 2019 (SCI-Expanded, Scopus)

97. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases

Ates O., YALÇIN Ş.

INDIAN JOURNAL OF CANCER , vol.56, no.2, pp.176-179, 2019 (SCI-Expanded, Scopus)

98. The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy

ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., et al.

ANTI-CANCER DRUGS , vol.30, no.3, pp.289-294, 2019 (SCI-Expanded, Scopus) Sustainable Development

99. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

ŞİMŞEK C., Esin E., YALÇIN Ş.

JOURNAL OF ONCOLOGY , vol.2019, 2019 (SCI-Expanded, Scopus) Sustainable Development

100. First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study

Beypinar I., ARAZ M., UYSAL M., YALÇIN Ş.

JOURNAL OF BUON , vol.24, no.1, pp.68-76, 2019 (SCI-Expanded, Scopus)

101. Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

YALÇIN Ş., Lacin S.

CANCER MANAGEMENT AND RESEARCH , vol.11, pp.7779-7785, 2019 (SCI-Expanded, Scopus)

102. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., et al.

LANCET ONCOLOGY , vol.19, no.11, pp.1437-1448, 2018 (SCI-Expanded, Scopus)

103. Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey

ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.29, no.4, pp.411-418, 2018 (SCI-Expanded, Scopus, TRDizin)

104. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

YALÇIN Ş., ÖZGÜROĞLU M., shitara K., bang y. j., bartolomeo m. d., mandala m., et al.

Lancet , vol.392, no.10142, pp.123-133, 2018 (SCI-Expanded, Scopus) Sustainable Development

105. A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity

Esin E., Telli T. A., YÜCE D., YALÇIN Ş.

TUMORI J , vol.104, no.3, pp.157-164, 2018 (SCI-Expanded, Scopus)

106. Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A single-center experience.

Telli T. A., Esin E., Yalcin S.

JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018 (SCI-Expanded, Scopus)

107. Recent advances in the management of pancreatic adenocarcinoma

Karakas Y., LAÇİN Ş., YALÇIN Ş.

EXPERT REVIEW OF ANTICANCER THERAPY , vol.18, no.1, pp.51-62, 2018 (SCI-Expanded, Scopus) Sustainable Development

108. A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study

YALÇIN Ş., Yildiz R., Dane F., Karaoglu A., Oksuzoglu B., ÖZYILKAN Ö., et al.

ONCOTARGETS AND THERAPY , vol.11, pp.1223-1228, 2018 (SCI-Expanded, Scopus)

109. Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience

YALÇIN Ş., HÜRMÜZ P., McQuinn L., Naing A.

JOURNAL OF GLOBAL ONCOLOGY , vol.4, 2017 (ESCI, Scopus) Sustainable Development

110. Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up

YALÇIN Ş., BAYRAM F., ERDAMAR ÇETİN A. S., Kucuk O., ORUÇ N., Coker A.

ARCHIVES OF MEDICAL SCIENCE , vol.13, no.2, pp.271-282, 2017 (SCI-Expanded, Scopus)

111. Renal cell cancer: overview of the current therapeutic landscape

ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , vol.16, no.9, pp.955-968, 2016 (SCI-Expanded, Scopus) Sustainable Development

112. A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer

Karakas Y., Esin E., LAÇİN Ş., Ceyhan K., HEPER A., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.9, pp.4815-4820, 2016 (SCI-Expanded, Scopus)

113. Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors

Yildiz Y., SÖKMENSÜER C., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.9, pp.5809-5817, 2016 (SCI-Expanded, Scopus)

114. Maintenance strategy in metastatic colorectal cancer: A systematic review

Esin E., YALÇIN Ş.

CANCER TREATMENT REVIEWS , vol.42, pp.82-90, 2016 (SCI-Expanded, Scopus)

115. Effects of infrared treatment on tocopherols, total phenolics and antioxidant activity of soybean samples

YALÇIN Ş., BAŞMAN A.

QUALITY ASSURANCE AND SAFETY OF CROPS & FOODS , vol.8, no.2, pp.273-281, 2016 (SCI-Expanded, Scopus)

116. Clinical Outcomes of Patients With Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-Use Trial of Sunitinib

Reichardt P., Kang Y., Rutkowski P., Schuette J., Rosen L. S., Seddon B., et al.

CANCER , vol.121, no.9, pp.1405-1413, 2015 (SCI-Expanded, Scopus)

117. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

Aykan N. F., YALÇIN Ş., Turhal N. S., Ozdogan M., Demir G., ÖZKAN M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.26, no.2, pp.145-153, 2015 (SCI-Expanded, Scopus, TRDizin)

118. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen

LAÇİN Ş., Esin E., Karakas Y., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.8, pp.1039-1042, 2015 (SCI-Expanded, Scopus)

119. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BENEKLİ M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., et al.

ONCOTARGETS AND THERAPY , vol.8, pp.1-5, 2015 (SCI-Expanded, Scopus)

120. EVALUATION OF QUALITY OF LIFE AND ANXIETY AND DEPRESISON LEVELS IN PATIENTS RECEIVING CHEMOTHERAPY FOR COLORECTAL CANCER: IMPACT OF PATIENT EDUCATION BEFORE TREATMENT INITIATION

Yalcin S., Polat U., Arpaci A., Demir S., Erdal S.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.10, pp.181, 2014 (SCI-Expanded, Scopus)

121. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded, Scopus)

122. Transient hypertrophic pyloric stenosis due to prostoglandin infusion

Sayer T., YALÇIN Ş., Bozkaya D., YİĞİT Ş., TANYEL F. C.

JOURNAL OF PERINATOLOGY , vol.34, no.10, pp.800-801, 2014 (SCI-Expanded, Scopus)

123. Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival

Turkoz F. P., Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., et al.

JOURNAL OF GASTRIC CANCER , vol.14, no.3, pp.164-172, 2014 (ESCI, Scopus)

124. Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation

POLAT Ü., Arpaci A., DEMİR S., Erdal S., YALÇIN Ş.

JOURNAL OF GASTROINTESTINAL ONCOLOGY , vol.5, no.4, pp.270-275, 2014 (ESCI, Scopus) Sustainable Development

125. Current and future systemic treatment options in metastatic pancreatic cancer

Arslan C., YALÇIN Ş.

JOURNAL OF GASTROINTESTINAL ONCOLOGY , vol.5, no.4, pp.280-295, 2014 (ESCI, Scopus) Sustainable Development

126. End-of-study results of Turkish gastric cancer patients from the global REGATE study

YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., et al.

JOURNAL OF BUON , vol.19, no.2, pp.377-387, 2014 (SCI-Expanded, Scopus)

127. Ultrasound Scanning of the Proximal Plexus in Diabetic Cervical Radiculoplexopathy

Yalcin S., Kara M., Tiftik T., Erden E., Ersoz M., Ozcakar L.

WEST INDIAN MEDICAL JOURNAL , vol.63, no.2, pp.208-209, 2014 (SCI-Expanded, Scopus)

128. Neuropathic cancer pain: What we are dealing with? How to manage it?

Esin E., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.7, pp.599-618, 2014 (SCI-Expanded, Scopus)

129. Analysis of Resected Gastric Cancer in Turkish Population

Demir G., Unsal D., Zengin N., ER Ö., Dane F., YALÇIN Ş.

HEPATO-GASTROENTEROLOGY , vol.61, no.129, pp.259-266, 2014 (SCI-Expanded, Scopus)

130. Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement

YALÇIN Ş., Trad D., Kader Y. A., Halawani H., Demir O. G., Mall R., et al.

FUTURE ONCOLOGY , vol.10, no.16, pp.2643-2657, 2014 (SCI-Expanded, Scopus)

131. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, pp.1709-1715, 2013 (SCI-Expanded, Scopus) Sustainable Development

132. Increasing performance of a hospital-based cancer registry: Hacettepe University hospitals experience

Kutluk T., HAYRAN K. M., Kilickap S., Yuce D., Celik I., Erman M., et al.

JOURNAL OF BUON , vol.18, no.4, pp.1088-1096, 2013 (SCI-Expanded, Scopus) Sustainable Development

133. Breast cancer in octogenarian women: clinical characteristics and outcome

Kuzan T. Y., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., et al.

JOURNAL OF BUON , vol.18, no.2, pp.328-334, 2013 (SCI-Expanded, Scopus) Sustainable Development

134. A review of the use of somatostatin analogs in oncology

Keskin O., YALÇIN Ş.

ONCOTARGETS AND THERAPY , vol.6, pp.471-483, 2013 (SCI-Expanded, Scopus)

135. Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial

YALÇIN Ş., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

ONCOLOGY , vol.85, no.6, pp.328-335, 2013 (SCI-Expanded, Scopus)

136. Transarterial Chemo and Radioembolization (Yttrium90) of Hepatic Metastasis of Neuroendocrine Tumors: Single Center Experience

Ozkan F., PEYNİRCİOĞLU B., ÇİL B. E., Yurttutan N., YALÇIN Ş., BALKANCI F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.23, no.1, pp.20-27, 2013 (SCI-Expanded, Scopus, TRDizin)

137. Salmonella gastroenteritis in children (clinical characteristics and antibiotic susceptibility): comparison of the years 1995-2001 and 2002-2008

Ince O. T., YALÇIN Ş., YURDAKÖK K., ÖZMERT E. N., Aydin A., Baris Z., et al.

TURKISH JOURNAL OF PEDIATRICS , vol.54, no.5, pp.465-473, 2012 (SCI-Expanded, Scopus)

138. Utility of "Over D1" or D1 Nodal Dissections in Predicting Outcome of Patients with Gastric Adenocarcinoma Treated with Postoperative Concurrent Chemoradiotherapy

SELEK U., Zorlu F., ÖZYİĞİT G., HÜRMÜZ P., YALÇIN Ş., CENGİZ M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.22, no.4, pp.233-238, 2012 (SCI-Expanded, Scopus, TRDizin)

139. Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Dogan E., YALÇIN Ş., Koca D., Olmez A.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.13, no.6, pp.2985-2990, 2012 (SCI-Expanded, Scopus)

140. Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group

ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.13, no.8, pp.4129-4131, 2012 (SCI-Expanded, Scopus)

141. Screening Colonoscopy Participation in Turkish Colorectal Cancer Patients and their First Degree Relatives

KILIÇKAP S., ARSLAN Ç., Rama D., YALÇIN Ş.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.13, no.6, pp.2829-2832, 2012 (SCI-Expanded, Scopus)

142. Evaluation of Dietary and Life-Style Habits of Patients with Gastric Cancer: A Case-Control Study in Turkey

YASSIBAŞ E., Arslan P., YALÇIN Ş.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.13, no.5, pp.2291-2297, 2012 (SCI-Expanded, Scopus)

143. Impact of Adjuvant Chemoradiotherapy for Rectal Cancer on the Long-Term Quality of Life and Late Side Effects: A Multicentric Clinical Evaluation by the Turkish Oncology Group

Kilic D., Yalman D., Aksu G., ATASOY B. M., Igdem S., DİNÇBAŞ H. F., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.13, no.11, pp.5741-5746, 2012 (SCI-Expanded, Scopus)

144. Nilotinib in Advanced Gastrointestinal Stromal Tumors after Imatinib and Sunitinib Therapy

Dizdar O., YALÇIN Ş.

HEPATO-GASTROENTEROLOGY , vol.58, no.112, pp.2012-2014, 2011 (SCI-Expanded)

145. Breast milk lead and cadmium levels from suburban areas of Ankara

Orun E., YALÇIN Ş., Aykut O., Orhan G., Morgil G. K., YURDAKÖK K., et al.

SCIENCE OF THE TOTAL ENVIRONMENT , vol.409, no.13, pp.2467-2472, 2011 (SCI-Expanded, Scopus) Sustainable Development

146. Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma.

Ricke J., Schuette K., Graziadei I. W., Jakob A., Verslype C., Sangro B., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011 (SCI-Expanded, Scopus)

147. Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011 (SCI-Expanded, Scopus)

148. Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report

DİZDAR Ö., YALÇIN Ş.

HEPATO-GASTROENTEROLOGY , vol.58, no.107, pp.859-860, 2011 (SCI-Expanded, Scopus)

149. The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.

Turhal N. S., Kilickap S., Yalcin S., Sezgin C., Yamac D., Akbulut H., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011 (SCI-Expanded, Scopus) Sustainable Development

150. Advances in the systemic treatment of pancreatic neuroendocrine tumors

Yalcin S.

CANCER TREATMENT REVIEWS , vol.37, no.2, pp.127-132, 2011 (SCI-Expanded, Scopus)

151. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study-A Turkish Oncology Group trial

Aykan N., Demir G., Disci R., Yalcin S., Turhal N. S., Ozdogan M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.4, 2011 (SCI-Expanded, Scopus)

152. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature

ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.22, no.1, pp.73-76, 2011 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

153. A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.4, 2011 (SCI-Expanded, Scopus) Sustainable Development

154. Zinc supplementation and TNF-alpha levels in vaccinated cardiac patients

YALÇIN Ş., Engur-Karasimav D., ALEHAN D., YURDAKÖK K., Ozkutlu S., COŞKUN T.

JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY , vol.25, no.2, pp.85-90, 2011 (SCI-Expanded, Scopus)

155. Hepatitis A seroprevalence among infants aged 12 months in Ankara

Ince O. T., YALÇIN Ş., YURDAKÖK K., ÖZMERT E. N.

TURKISH JOURNAL OF PEDIATRICS , vol.53, no.1, pp.114-116, 2011 (SCI-Expanded, Scopus) Sustainable Development

156. The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting

KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.

HEPATO-GASTROENTEROLOGY , vol.58, no.105, pp.208-212, 2011 (SCI-Expanded, Scopus)

157. Why are they having infant colic? A nested case-control study

YALÇIN Ş., ORUN E., MUTLU B., MADENDAG Y., Sinici İ., DURSUN A., et al.

PAEDIATRIC AND PERINATAL EPIDEMIOLOGY , vol.24, no.6, pp.584-596, 2010 (SCI-Expanded, Scopus)

158. Serological response to influenza vaccine after hematopoetic stem cell transplantation

YALÇIN Ş., Kondolot M., Albayrak N., Altas A. B., Karacan Y., Kuskonmaz B. B., et al.

ANNALS OF HEMATOLOGY , vol.89, no.9, pp.913-918, 2010 (SCI-Expanded, Scopus) Sustainable Development

159. Sensitivity and specificity of bloody diarrhea in shigella gastroenteritis

ÖZMERT E. N., ORUN E., ŞENGELEN M., YALÇIN Ş., YURDAKÖK K., GÜR D.

TURKISH JOURNAL OF PEDIATRICS , vol.52, no.5, pp.488-490, 2010 (SCI-Expanded, Scopus) Sustainable Development

160. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia

Aytac Ş. S., YALÇIN Ş., Cetin M., Yetgin S., GÜMRÜK F., Tuncer M., et al.

Pediatric Hematology and Oncology , vol.27, no.5, pp.333-343, 2010 (SCI-Expanded, Scopus) Sustainable Development

161. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Ocvirk J., Brodowicz T., Wrba F., Ciuleanu T. E., Kurteva G., Beslija S., et al.

WORLD JOURNAL OF GASTROENTEROLOGY , vol.16, no.25, pp.3133-3143, 2010 (SCI-Expanded, Scopus)

162. FEEDING PRACTICES OF 12-23 MONTHS AGED CHILDREN IN TURKEY

Koksal E., YALÇIN Ş., Tezel B., Pekcan G., Sahin S., Ozbas S., et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION , vol.50, 2010 (SCI-Expanded, Scopus)

163. Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts)

Wu C., Soloviev V., Semkina E., Ter-Ovanesov M., Babu K. G., Vila A., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded, Scopus) Sustainable Development

164. The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening

Arslan C., Kilickap S., Rama D., Yalcin S.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded, Scopus)

165. Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches

Ter-Ovanesov M., Kulig J., Munasypov F., Bang Y., Yalcin S., Roth A., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded, Scopus) Sustainable Development

166. Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts)

Zalcberg J. R., Mohandas K. M., Kang Y., Bang Y., Ter-Ovanesov M., Ben Ahmed S., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded, Scopus)

167. Registry of Gastric Cancer Treatment Evaluation (REGATE): Variation in nonsurgical therapies

Yalcin S., Serraiva M., Arbeloa P., Kang W., Bang Y., Gumus M., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010 (SCI-Expanded, Scopus)

168. The Factors that have a Role in Variability for Temperature

YALÇIN Ş., Aydemir O., Erkul E., KARABULUT E., Akca T.

JOURNAL OF TROPICAL PEDIATRICS , vol.56, no.1, pp.53-59, 2010 (SCI-Expanded, Scopus)

169. Maternal and environmental determinants of breast-milk mercury concentrations

YALÇIN Ş., YURDAKÖK K., Yalcin S. S., Engur-Karasimav D., COŞKUN T.

TURKISH JOURNAL OF PEDIATRICS , vol.52, no.1, pp.1-9, 2010 (SCI-Expanded, Scopus)

170. Factors associated with breastfeeding initiation time in a Baby-Friendly Hospital

Orun E., YALÇIN Ş., Madendag Y., Ustunyurt-Eras Z., Kutluk S., YURDAKÖK K.

TURKISH JOURNAL OF PEDIATRICS , vol.52, no.1, pp.10-16, 2010 (SCI-Expanded, Scopus)

171. Feeding on one side or both sides in a breast-feeding session

KONDOLOT M., YALÇIN Ş., YURDAKÖK K.

PEDIATRICS INTERNATIONAL , vol.51, no.6, pp.817-820, 2009 (SCI-Expanded, Scopus)

172. Seasonal and gender differences in hemoglobin value in infants at 5-7 months of age

YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.

TURKISH JOURNAL OF PEDIATRICS , vol.51, no.6, pp.572-577, 2009 (SCI-Expanded, Scopus)

173. Effects of early feed restriction on live performance, carcass characteristics, meat and liver composition, some blood parameters, heterophil-lymphocyte ratio, antibody production and tonic immobility duration

Onbasilar E. E., Yalcin S., Torlak E., Ozdemir P.

TROPICAL ANIMAL HEALTH AND PRODUCTION , vol.41, no.7, pp.1513-1519, 2009 (SCI-Expanded, Scopus)

174. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial

Curran D., Pozzo C., Zaluski J., Dank M., Barone C., Valvere V., et al.

QUALITY OF LIFE RESEARCH , vol.18, no.7, pp.853-861, 2009 (SCI-Expanded, Scopus)

175. Changes in serum leptin concentrations in rats according to malnutrition models and effects of carnitine supplementation on catch-up growth

ONBAŞILAR İ., YALÇIN Ş.

REVUE DE MEDECINE VETERINAIRE , vol.160, no.7, pp.362-369, 2009 (SCI-Expanded, Scopus) Sustainable Development

176. Comparison of acute bloody and watery diarrhea: a case control study

Kuskonmaz B. B., YURDAKÖK K., YALÇIN Ş., Ozmert E.

TURKISH JOURNAL OF PEDIATRICS , vol.51, no.2, pp.133-140, 2009 (SCI-Expanded, Scopus) Sustainable Development

177. Nutrition and Gastric Cancer in Turkey

YALÇIN Ş.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , vol.61, no.6, pp.900-902, 2009 (SCI-Expanded, Scopus) Sustainable Development

178. NFKB1-94 Insertion/Deletion ATTG Polymorphism in Gastroenteropancreatic Neuroendocrine Tumors

Burnik F. S., YALÇIN Ş.

CHEMOTHERAPY , vol.55, no.5, pp.381-385, 2009 (SCI-Expanded, Scopus)

179. Effects of the usage of dried brewing yeast in the diets on the performance, egg traits and blood parameters in quails

Yalcin S., Erol H., Oezsoy B., Onbasilar I., Yalcin S.

ANIMAL , vol.2, no.12, pp.1780-1785, 2008 (SCI-Expanded, Scopus)

180. Clinical presentation and management of Gastroesophageal reflux disease in a referral center in Turkey

YALÇIN Ş., ÇİFTÇİ A. Ö., Senocak M. E., TANYEL F. C.

EUROPEAN JOURNAL OF PEDIATRIC SURGERY , vol.18, no.3, pp.180-184, 2008 (SCI-Expanded, Scopus)

181. Prophylactic use of acetaminophen in children vaccinated with diphtheria-tetanus-pertussis

YALÇIN Ş., Gumus A., YURDAKÖK K.

WORLD JOURNAL OF PEDIATRICS , vol.4, no.2, pp.127-129, 2008 (SCI-Expanded, Scopus)

182. Validity of using pallor to detect children with mild anemia

YURDAKÖK K., Guner S. N., YALÇIN Ş.

PEDIATRICS INTERNATIONAL , vol.50, no.2, pp.232-234, 2008 (SCI-Expanded, Scopus)

183. Seasonal and gender differences in the prevalence of infant anemia

YALÇIN Ş., Dut R., YURDAKÖK K., Ozmert E.

PEDIATRICS , vol.121, 2008 (SCI-Expanded, Scopus)

184. Sparing of previously irradiated skin from eriotinib-induced acneiform rash

YALÇIN Ş., Dizdar O., Yalcin B., Goekoez Ö.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY , vol.58, no.1, pp.178-179, 2008 (SCI-Expanded, Scopus)

185. Current medical treatment of pancreatic neuroendocrine tumors

Yalcin S., Oyan B., Bayraktar Y.

HEPATO-GASTROENTEROLOGY , vol.54, no.73, pp.278-284, 2007 (SCI-Expanded, Scopus)

186. Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement

Kilickap S., Aksoy S., Dincer M., Saglam E. A., Yalcin S.

SOUTHERN MEDICAL JOURNAL , vol.99, no.10, pp.1137-1139, 2006 (SCI-Expanded, Scopus) Sustainable Development

187. Lightning: A risk factor for squamous cell carcinoma of the skin

Purnak T., Kilickap S., Aksoy S., Yalcin S.

CLINICAL ONCOLOGY , vol.18, no.8, pp.636, 2006 (SCI-Expanded, Scopus)

188. Orbital metastasis from adenocarcinoma of the colon

Dizdar O., Aksoy S., Kilickap S., Yalcin S.

SOUTHERN MEDICAL JOURNAL , vol.98, no.8, pp.846-847, 2005 (SCI-Expanded, Scopus)

189. Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient

Aksoy S., KARACA B., DİNÇER M., Yalcin S.

ANNALS OF PHARMACOTHERAPY , vol.39, no.3, pp.573-574, 2005 (SCI-Expanded, Scopus) Sustainable Development

190. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: Results of single-center study of 45 patients

Altundag O., Gullu I., Altundag K., Yalcin S., Ozyar E., Cengiz M., et al.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK , vol.27, no.1, pp.15-21, 2005 (SCI-Expanded, Scopus)

191. Diagnosis and management of cholangiocarcinomas: A comprehensive review

Yalcin S.

HEPATO-GASTROENTEROLOGY , vol.51, no.55, pp.43-50, 2004 (SCI-Expanded, Scopus)

192. Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)

OYAN ULUÇ B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., et al.

ANNALS OF ONCOLOGY , vol.15, pp.153, 2004 (SCI-Expanded, Scopus)

193. Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy

Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., et al.

MEDICAL ONCOLOGY , vol.21, no.3, pp.211-215, 2004 (SCI-Expanded, Scopus)

194. Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer

Yalcin S., Oksuzoglu B., Tekuzman G., Engin H., Celik I., Turker A., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.33, no.11, pp.580-583, 2003 (SCI-Expanded, Scopus) Sustainable Development

195. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors

Karaoglu A., Yalcin S., Tekuzman G., Kars A., Celik I., Guler N., et al.

TUMORI , vol.89, no.2, pp.141-145, 2003 (SCI-Expanded, Scopus) Sustainable Development

196. Reactivation of hepatitis B virus infection in pancreatic cancer: a case report

Oksuzoglu B., Kilickap S., Yalcin S.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.12, pp.543-545, 2002 (SCI-Expanded, Scopus)

197. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients

Ozturk M., Barista I., Altundag M., Turker A., Yalcin S., Celik I., et al.

CHEMOTHERAPY , vol.48, no.5, pp.252-258, 2002 (SCI-Expanded, Scopus) Sustainable Development

198. Role of self-expandable metal stents (SEMS) in colorectal malignancy

Yalcin S., Singh S., Gagneja H., Kalha I., Patel M., Lenzi R., et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY , vol.97, no.9, 2002 (SCI-Expanded, Scopus)

199. Abdominal pain in a diabetic myeloma patient with cirrhosis

GÖNEN C., Oksuzoglu B., Yalcin S.

POSTGRADUATE MEDICAL JOURNAL , vol.78, no.920, pp.375-376, 2002 (SCI-Expanded, Scopus)

200. Squamous cell carcinoma of the tongue in a patient with Fanconi's anemia: a case report and review of the literature

Oksuzoglu B., Yalcin S.

ANNALS OF HEMATOLOGY , vol.81, no.5, pp.294-298, 2002 (SCI-Expanded, Scopus)

201. The effects of tannic acid and lignosulfonate treatments of sunflower seed meal on the digestibility and rumen degradability characteristics of some nutrients in rams

Yalcin S., Sehu A., Guclu B., Onbasilar İ., Sarifakiogullari K.

TURKISH JOURNAL OF VETERINARY & ANIMAL SCIENCES , vol.26, no.4, pp.805-813, 2002 (SCI-Expanded, Scopus, TRDizin)

202. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy

Lenzi R., Yalcin S., Evans D., Abbruzzese J.

CANCER INVESTIGATION , vol.20, no.4, pp.464-472, 2002 (SCI-Expanded, Scopus) Sustainable Development

203. Leptomeningeal infiltration of malignant mesothelioma

Oksuzoglu B., Yalcin S., Erman M., Dagdelen S.

MEDICAL ONCOLOGY , vol.19, no.3, pp.167-169, 2002 (SCI-Expanded, Scopus)

204. Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer

Oyan B., Engin H., Yalcin S.

MEDICAL ONCOLOGY , vol.19, no.3, pp.177-179, 2002 (SCI-Expanded, Scopus)

205. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma

Yalcin S., Erman M., Tekuzman G., Ruacan S.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.23, no.4, pp.384-385, 2000 (SCI-Expanded, Scopus)

206. Primary low grade B-cell lymphoma of the dura in an immunocompetent patient

Altundag M., Ozisik Y., Yalcin S., Akyol F., Uner A.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.19, no.2, pp.249-251, 2000 (SCI-Expanded)

207. Management of patients with cancer of unknown primary site - The Hainsworth/Greco article reviewed

Lenzi R., Yalcin S.

ONCOLOGY-NEW YORK , vol.14, no.4, pp.576-578, 2000 (SCI-Expanded, Scopus)

208. Organ preservation by induction chemotherapy plus radiotherapy in locally advanced larynx and hypopharynx cancers: Preliminary results.

Gullu Y., Altundag M., Yalcin S., Altundag O., Tekuzman G., Ozyar E., et al.

ANNALS OF ONCOLOGY , vol.11, pp.94, 2000 (SCI-Expanded, Scopus) Sustainable Development

209. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., Ozisik Y., et al.

JOURNAL OF SURGICAL ONCOLOGY , vol.73, no.1, pp.12-16, 2000 (SCI-Expanded, Scopus)

210. DEVELOPMENT AND APPLICATION OF A SIMPLE EXPERT SYSTEM FOR THE INTERPRETATION OF THE ANTEPARTUM FETAL HEART-RATE TRACINGS (VERSION 88/2.29)

BEKSAC M., OZDEMIR K., KARAKAS U., YALCIN S., KARAAGAOGLU E.

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY , vol.37, no.2, pp.133-141, 1990 (SCI-Expanded, Scopus)

211. COMPUTERIZED ANALYSIS OF ANTEPARTUM FETAL HEART-RATE TRACINGS IN NORMAL PREGNANCIES (VERSION 88/2.29)

BEKSAC M., KARAKAS U., YALCIN S., OZDEMIR K., SANLITURK E.

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY , vol.37, no.2, pp.121-132, 1990 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 41

1. Incidence of unexpected lymph node positivity and its prognostic impact in patients undergoing pulmonary metastasectomy

KUMBASAR U., DİZDAR Ö., UYSAL S., DİKMEN E., YALÇIN Ş.

14th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 28 November 2024, (Summary Text)

2. Prognostic Impact of Circulating Angiogenic Factors in 90Y Microsphere Treatment

MAVİ M. E., VOLKAN SALANCI B., LAY İ., ELDEM F. G., PEYNİRCİOĞLU B., YALÇIN Ş., et al.

55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON), Jodhpur, India, 16 - 19 November 2023, (Summary Text)

3. the role of neoadjuvant radiotherapy in rectal cancer: hacettepe university experience

HÜRMÜZ P., TİLKİ B., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., et al.

9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text) Sustainable Development

4. prognostic significance of ıgf-1 in hepatocellular cancer patients turkish validation study

LAÇİN Ş., Karakas Y., Abdel Wahab R., HASSAN M., Lianchun X., KASEB A., et al.

9 th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text) Sustainable Development

5. Definitive Chemoradiotherapy in Esophageal Squamous Cell Cancer: A Single Center Experience

YILMAZ M. T., HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., et al.

9th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 6 - 08 December 2019 Sustainable Development

6. importance of serum vegfa level in hepatocellular cancer patients, its relationship with clinicoppathologic parameters

LAÇİN Ş., Karakas Y., YALÇIN Ş.

9 th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text) Sustainable Development

7. non-operative management of rectal cancer: hacettepe university experience

TİLKİ B., HÜRMÜZ P., CENGİZ M., ZORLU A. F., ÖZYİĞİT G., YILDIZ F., et al.

9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text) Sustainable Development

8. DEFİNİTİVE CHEMORADİOTHERAPY İN ESOPHAGEAL S@UAMOUS CELL CANCER A SİNGLE CENTER EXPERİENCE

HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., YALÇIN Ş., et al.

9 th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text) Sustainable Development

9. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text)

10. A Single Center Experience of Neoadjuvant Radiotherapy in Rectal Cancer

HÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., et al.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5, (Full Text) Sustainable Development

11. The Role of Radiotherapy /- Chemotherapy in the treatment of Rectal Cancer: Single Center Experience

TİLKİ B., HÜRMÜZ P., CENGİZ M., YILDIZ F., ZORLU A. F., ÖZYİĞİT G., et al.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5, (Full Text) Sustainable Development

12. Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).

Alsina M., Tabernero J., Shitara K., Doi T., Dvorkin M., Mansoor W., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text) Sustainable Development

13. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

14. COMBINATION OF OxALIPLATIN, CAPECITABINE,t r a s t u z u m a b a n d c h e m o r a d io t h e r a p y INPATIENTS WITH GASTRIC CANCER

ABALI H., YALÇIN Ş., ÖNAL H. C., DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., et al.

8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018, (Full Text) Sustainable Development

15. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi

GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.

2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, (Full Text) Sustainable Development

16. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali H., Yalcin S., Onal C., Dane F., Oksuzoglu B., Ozdemir N., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36, (Summary Text) Sustainable Development

17. Economic Burden of Gastric Cancer in Turkey

BİLİCİ A., GÜMÜŞ M., MALHAN B. S., Öksüz E., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN Ş.

ISPOR 20th Annual European Congress, 4 - 08 November 2017, (Full Text) Sustainable Development

18. Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

Escobar N. E. I., Luaces P. L., Valdes L. S., Silva C. V., Ramos T. C., Strumberg D., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35, (Summary Text) Sustainable Development

19. Beyin Tumorlerinde Serum Peptidomik Analiz

PINAR A., KUTLUK M. T., Mut A. M., KARAHAN S., AKALAN N., YALÇIN Ş., et al.

22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017, (Summary Text)

20. FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER

ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B., et al.

International Congress on Oncological Sciences, 27 September - 01 October 2017, (Summary Text) Sustainable Development

21. A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34, (Summary Text)

22. Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)

23. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors

Goker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., et al.

24. frequency of c Met HGF and HER 2 expression and evaluation of their association with clinicopathological and prognostic factors in gastric cancer

YALÇIN Ş., yetkin y., SÖKMENSÜER C.

gastrointestinal cancers symposium 2015, 15 - 17 January 2015 Sustainable Development

25. Frequency of c-Met, HGF, and HER-2 expression and evaluation of their association with clinicopathologic and prognostic factors in gastric cancer.

YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 15 - 17 January 2015, vol.33, (Summary Text) Sustainable Development

26. Predictors of outcome in patients with advanced nonseminamatous germ cell testicular tumors.

Yetisyigit T., Babacan N., Urun Y., Seber S., Arpaci E., Clhan S., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

27. Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).

Ricke J., Schutte K., Rosmorduc O., Peck-Radosavljevic M., Verslype C., Sangro B., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

28. Evaluation of the frequency of c-Met and HER2 expressions in gastric carcinoma and their association with clinicopathologic factors

YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32, (Summary Text)

29. The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.

Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

30. Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)

Strumberg D., Schultheis B., Ebert M. P., Kerkhoff A., Hofheinz R. D., Behringer D. M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) Sustainable Development

31. Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results

Ravaud A., Barrios C. H., Alekseev B. Y., Tay M. H., Agarwala S. S., Yalcin S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

32. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text) Sustainable Development

33. Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.

Yalcin S., Buyukberber S., Yilmaz U., Lee P., Srimuninnimit V., Lin P., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)

34. Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial

Hobday T., Becerra C., YALÇIN Ş., Panneerselvam A., Saletan S., Hainsworth J.

76th Annual Scientific Meeting of the American-College-of-Gastroenterology, Washington, Kiribati, 28 October - 02 November 2011, vol.106, (Summary Text)

35. POST-STUDY TREATMENT OPTIONS ARE LIMITED IN PATIENTS WITH ADVANCED NET: ANALYSIS OF POST-PROGRESSION THERAPIES FROM THE RADIANT-2 TRIAL

Peeters M., Becerra C., Panneerselvam A., Saletan S., YALÇIN Ş.

European-Society-for-Medical-Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22 - 25 June 2011, vol.22, (Summary Text)

36. Serological response to influenza vaccine haematopoetic stem cell transplantation patients

YALÇIN Ş., Kondolot M., Albayrak N., Altas B., Karacan Y., KUŞKONMAZ B. B., et al.

36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Austria, 21 - 24 March 2010, vol.45, (Summary Text) Sustainable Development

37. REGATE: What happens to gastric cancer treatment in the real world?

Ter-Ovanesov M., Bang Y., Wu C., Yalcin S., Roth A., Zalcberg J., et al.

Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 29 June 2006, vol.17, pp.31, (Summary Text) Sustainable Development

38. Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival and relapse (Turkish Oncology Group Study)

Demir G., Zengin N., Yildiz O., Ozdamar S., Aykan F., Er O., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.324-325, (Summary Text) Sustainable Development